

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI632615

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
SEQUENCE:	2
CONVEYING PARTY DATA	
Name	Execution Date
Aegis Therapeutics, LLC	11/13/2024
RECEIVING PARTY DATA	
Company Name:	NEF Royalty Sub LLC
Street Address:	601 Lexington Avenue, 54th Floor
City:	New York
State/Country:	NEW YORK
Postal Code:	10022
PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	10576156
Patent Number:	10682414
Patent Number:	11173209
Patent Number:	11191838
Patent Number:	11744895
Patent Number:	11717571
Patent Number:	11918655
Application Number:	18327621
Application Number:	18824077
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2026626000
Email:	akwon@cov.com
Correspondent Name:	Covington Burling LLP
Address Line 1:	ONE CITY CENTER, 850 TENTH ST NW
Address Line 4:	WASHINGTON, DISTRICT OF COLUMBIA 20001
ATTORNEY DOCKET NUMBER:	34550.00121

<b>NAME OF SUBMITTER:</b>	Ms. Ashley Kwon
<b>SIGNATURE:</b>	Ms. Ashley Kwon
<b>DATE SIGNED:</b>	11/14/2024
<b>Total Attachments: 17</b> source=Neffy - Patent Security Agreement#page1.tiff source=Neffy - Patent Security Agreement#page2.tiff source=Neffy - Patent Security Agreement#page3.tiff source=Neffy - Patent Security Agreement#page4.tiff source=Neffy - Patent Security Agreement#page5.tiff source=Neffy - Patent Security Agreement#page6.tiff source=Neffy - Patent Security Agreement#page7.tiff source=Neffy - Patent Security Agreement#page8.tiff source=Neffy - Patent Security Agreement#page9.tiff source=Neffy - Patent Security Agreement#page10.tiff source=Neffy - Patent Security Agreement#page11.tiff source=Neffy - Patent Security Agreement#page12.tiff source=Neffy - Patent Security Agreement#page13.tiff source=Neffy - Patent Security Agreement#page14.tiff source=Neffy - Patent Security Agreement#page15.tiff source=Neffy - Patent Security Agreement#page16.tiff source=Neffy - Patent Security Agreement#page17.tiff	

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of November 13, 2024 (this “**Agreement**”), is made by Aegis Therapeutics, LLC a California limited liability company (“**Grantor**”), in favor of NEF Royalty Sub LLC, a Delaware limited liability company (together with its successors, transferees and assignees, “**Secured Party**”).

W I T N E S S E T H :

WHEREAS, pursuant to the Security Agreement, dated as of November 13, 2024 (as amended, supplemented or otherwise modified from time to time, the “**Security Agreement**”), by and between Grantor and Secured Party, Grantor is required to execute and deliver this Agreement and to grant to Secured Party a continuing security interest in Grantor’s Patent Rights to secure the Secured Obligations;

WHEREAS, Grantor has duly authorized the execution, delivery and performance of this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor agrees, for the benefit of Secured Party, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

SECTION 2. Grant of Security Interest. Grantor hereby grants to Secured Party a continuing security interest in all of Grantor’s right, title and interest in and to the Patent Rights, including each United States issued patent and patent application referred to on Schedule I attached hereto.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by Grantor for the purpose of recording the grant of security interest to Secured Party in the Patent Rights with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to Secured Party for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of Secured Party thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Termination. Upon the occurrence of a termination pursuant to Section 12 of the Security Agreement, the security interest granted herein shall automatically terminate with respect to the Patent Rights.

SECTION 5. Acknowledgment. Grantor and Secured Party do hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest in the Patent Rights granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. In the event of any conflict between the terms of this

Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern,

SECTION 6. Effectiveness. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by email with PDF attachment shall be considered original executed counterparts.

SECTION 7. Governing Law. This Agreement shall be governed exclusively by the laws of the State of New York, United States of America, without giving effect to its conflict of law provisions.

*[Signature Page Follows]*

IN WITNESS WHEREOF, Grantor hereto has caused this Agreement to be duly executed and delivered by as of the date first above written.

AEGIS THERAPEUTICS, LLC

By: DocuSigned by:  
*Craig Chambliss*  
1202E894FB0E415...  
Name: Craig Chambliss  
Title: President and Chief Executive Officer

SCHEDULE I  
to Patent Security Agreement

Assignee of Record	Country Name	Serial #	Filed Date	Status	Patent #	Issue Date	Stated Expiration Date	Title	Reference #
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	15/890,131	2/6/2018	ISSUED	10,576,156	3/3/2020	2/6/2038	COMPOSITIONS FOR DRUG ADMINISTRATION	148570-003401
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	EUROPE	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003403-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	JAPAN	2020-505498	2/6/2019	ISSUED	6941224	9/7/2021	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003404-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	CANADA	3088989	2/6/2019	ISSUED	3088989	3/7/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003405-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SPAIN	P202090032	2/6/2019	ISSUED	2791775	1/13/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003406-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	ISRAEL	276485	2/6/2019	ALLOWED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003407-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	CHINA	201980001004.2	2/6/2019	ISSUED	110505873 (Chinese Invention Patent No. ZL2019800010042)	12/30/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003408-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	EURASIAN PATENT	202091615	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003409-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	JAPAN	2021-135018	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003414-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	AUSTRALIA	2019217643	2/6/2019	ISSUED	2019217643	2/10/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003417-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	HONG KONG	62020007689.6	2/6/2019	ISSUED	40018410	5/12/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003418-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	BRAZIL	112020015646-9	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003419-S



AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	16/420,044	5/22/2019	ISSUED	10,682,414	6/16/2020	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003421-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	EUROPE	24153614.3	2/6/2019	PENDING			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003423-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	MEXICO	MX/a/2020/008132	2/6/2019	ISSUED	400406	2/28/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003426-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	INDIA	202017032361	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003427-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	INDIA	202318051778	2/6/2019	PENDING				INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-0034XX-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SOUTH KOREA	10-2020-7024852	2/6/2019	ISSUED	10-2375232	3/11/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003428-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SINGAPORE	11202007527X	2/6/2019	ISSUED	11202007527X	11/29/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003429-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SOUTH AFRICA	2020/04564	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003434-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	GERMANY	112019000683.5	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003435-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	UNITED KINGDOM	2012086.1	2/6/2019	ISSUED	2583051	12/2/2020	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003436-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	UNITED KINGDOM	2016960.3	2/6/2019	ISSUED	2587934	1/19/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003437-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	UKRAINE	a202004832	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003438-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	UNITED KINGDOM	2117505.4	2/6/2019	ISSUED	2600026	10/12/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003439-S
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	16/678,347	11/8/2019	ISSUED	11,173,209	11/16/2021	2/6/2038	COMPOSITIONS FOR DRUG ADMINISTRATION	148570-003441
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	MEXICO	MX/a/2023/002506	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003446-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	AUSTRALIA	2021254650	2/6/2019	ISSUED	2021254650	6/6/2024	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003447-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	CHINA	202211604693.6	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003448-S
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	16/869,461	5/7/2020	ISSUED	11,191,838	12/7/2021	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003451-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	ALBANIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003452-S

**PATENT**

**REEL: 069261 FRAME: 0563**

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	AUSTRIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003453-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS, INC. *	BOSNIA	19751807.9	2/6/2019	ISSUED	E04278	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003454-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	BELGIUM	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003455-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	BULGARIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003456-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SWITZERLAND	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003457-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	CYPRUS	19751807.9	2/6/2019	ISSUED	CY1125856	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003458-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	CZECH REPUBLIC	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003459-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	GERMANY	19751807.9	2/6/2019	ISSUED	602019021146.5	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003460-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	DENMARK	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003462-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	ESTONIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003463-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SPAIN	19751807.9	2/6/2019	ISSUED	2935684	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003464-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	FINLAND	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003465-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	FRANCE	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003466-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	GREECE	19751807.9	2/6/2019	ISSUED	3111832	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003467-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	CROATIA	19751807.9	2/6/2019	ISSUED	P20221525	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003468-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	HUNGARY	19751807.9	2/6/2019	ISSUED	E060917	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003469-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	IRELAND	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003470-S
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	17/396,044	8/6/2021	ISSUED	11,744,895	9/5/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003471-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	ICELAND	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003472-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	ITALY	19751807.9	2/6/2019	ISSUED	502023000002073	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003473-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	LITHUANIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003474-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	LUXEMBOURG	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003475-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	LATVIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003476-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	MONACO	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003477-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	MONTENEGRO	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003478-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	MACEDONIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003479-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	MALTA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003480-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	NETHERLANDS	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003482-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	NORWAY	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003483-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS, INC. *	POLAND	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003484-S



AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	PORTUGAL	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003485-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS, INC. *	ROMANIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003486-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SERBIA	19751807.9	2/6/2019	ISSUED	63866	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003487-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SWEDEN	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003488-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SLOVENIA	19751807.9	2/6/2019	ISSUED	3678649	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003489-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SLOVAK REPUBLIC	19751807.9	2/6/2019	ISSUED	E41034	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003490-S

AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	18/049,936	10/26/2022	ISSUED	11,717,571	8/8/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003491-S PE
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SAN MARINO	19751807.9	2/6/2019	ISSUED	SM-1-202300099	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003492-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	TURKEY	19751807.9	2/6/2019	ISSUED	2023/000424	10/26/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	DIA REF?
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	HONG KONG	42021033577.4	2/6/2019	ISSUED	40043811	9/16/2022	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003497-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	HONG KONG	42023081191.1	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003498-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	HONG KONG	42022059055.8	2/6/2019	ISSUED	40069350	2/10/2023	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-003499-S

AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SINGAPORE	10202303206T	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-013409-S
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	18/327,621	6/1/2023	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-013411-S
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	18/206,881	6/7/2023	ISSUED	11,918,655	3/5/2024	2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-013421-S PE
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	AUSTRALIA	2024201523	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-013447-S
AEGIS THERAPEUTICS, LLC ARS PHARMACEUTICALS OPERATIONS, INC.	SOUTH KOREA	10-2024-7003430	2/6/2019	PUBLISHED			2/6/2039	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	148570-013449-S
AEGIS THERAPEUTICS, LLC [licensee: ARS PHARMACEUTICALS, INC.]	UNITED STATES	18/824,077	9/4/2024	PENDING			2/6/2039	COMPOSITIONS FOR DRUG ADMINISTRATION	148570-013451

\* Name change in progress  
from "ARS Pharmaceuticals,  
Inc." to "ARS  
Pharmaceuticals  
Operations, Inc."

**PATENT**

**REEL: 069261 FRAME: 0571**

**RECORDED: 11/14/2024**